Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:34 UTC |
---|
HMDB ID | HMDB0014322 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Fluvoxamine |
---|
Description | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. |
---|
Structure | COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3 |
---|
Synonyms | Value | Source |
---|
Fluvoxamine maleate | HMDB | Fluvoxamine-CR | HMDB | Floxyfral | HMDB | Novo-fluvoxamine | HMDB | Novopharm brand OF fluvoxamine maleate | HMDB | PMS-Fluvoxamine | HMDB | Neuraxpharm brand OF fluvoxamine maleate | HMDB | Declimed brand OF fluvoxamine maleate | HMDB | Desiflu | HMDB | Dumirox | HMDB | Fluvoxadura | HMDB | Fluvoxamin stada | HMDB | Fluvoxamin beta | HMDB | Fluvoxamin-ratiopharm | HMDB | Fluvoxamina geminis | HMDB | Geminis, fluvoxamina | HMDB | Luvox | HMDB | Nu fluvoxamine | HMDB | Nu-pharm brand OF fluvoxamine maleate | HMDB | PMS Fluvoxamine | HMDB | Pharmascience brand OF fluvoxamine maleate | HMDB | Solvay brand OF fluvoxamine maleate | HMDB | Stadapharm brand OF fluvoxamine maleate | HMDB | Aliud brand OF fluvoxamine maleate | HMDB | Faverin | HMDB | Fevarin | HMDB | Fluvoxamin al | HMDB | Fluvoxamine maleate, (e)-isomer | HMDB | Geminis brand OF fluvoxamine maleate | HMDB | Nu-fluvoxamine | HMDB | Betapharm brand OF fluvoxamine maleate | HMDB | Ratio fluvoxamine | HMDB | Fluvoxamin neuraxpharm | HMDB | Fluvoxamin ratiopharm | HMDB | Fluvoxamin-neuraxpharm | HMDB | Fluvoxamine, (Z)-isomer | HMDB | Merck dura brand OF fluvoxamine maleate | HMDB | Novo fluvoxamine | HMDB | Nu pharm brand OF fluvoxamine maleate | HMDB | Ratiopharm brand OF fluvoxamine maleate | HMDB | Ratio-fluvoxamine | HMDB |
| Show more...
---|
Chemical Formula | C15H21F3N2O2 |
---|
Average Molecular Weight | 318.3346 |
---|
Monoisotopic Molecular Weight | 318.155512541 |
---|
IUPAC Name | (2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine |
---|
Traditional Name | luvox |
---|
CAS Registry Number | 54739-18-3 |
---|
SMILES | COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F |
---|
InChI Identifier | InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3 |
---|
InChI Key | CJOFXWAVKWHTFT-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Trifluoromethylbenzenes |
---|
Direct Parent | Trifluoromethylbenzenes |
---|
Alternative Parents | |
---|
Substituents | - Trifluoromethylbenzene
- Dialkyl ether
- Ether
- Alkyl fluoride
- Organopnictogen compound
- Hydrocarbon derivative
- Primary amine
- Organooxygen compound
- Organonitrogen compound
- Organofluoride
- Organohalogen compound
- Primary aliphatic amine
- Organic oxygen compound
- Organic nitrogen compound
- Amine
- Alkyl halide
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 120 - 122.5 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.0073 g/L | Not Available | LogP | 3.2 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | CBM | 177.0 | 30932474 |
|
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Fluvoxamine,1TMS,isomer #1 | COCCCCC(=NOCCN[Si](C)(C)C)C1=CC=C(C(F)(F)F)C=C1 | 2037.1 | Semi standard non polar | 33892256 | Fluvoxamine,1TMS,isomer #1 | COCCCCC(=NOCCN[Si](C)(C)C)C1=CC=C(C(F)(F)F)C=C1 | 2161.3 | Standard non polar | 33892256 | Fluvoxamine,1TMS,isomer #1 | COCCCCC(=NOCCN[Si](C)(C)C)C1=CC=C(C(F)(F)F)C=C1 | 2495.7 | Standard polar | 33892256 | Fluvoxamine,2TMS,isomer #1 | COCCCCC(=NOCCN([Si](C)(C)C)[Si](C)(C)C)C1=CC=C(C(F)(F)F)C=C1 | 2294.3 | Semi standard non polar | 33892256 | Fluvoxamine,2TMS,isomer #1 | COCCCCC(=NOCCN([Si](C)(C)C)[Si](C)(C)C)C1=CC=C(C(F)(F)F)C=C1 | 2257.7 | Standard non polar | 33892256 | Fluvoxamine,2TMS,isomer #1 | COCCCCC(=NOCCN([Si](C)(C)C)[Si](C)(C)C)C1=CC=C(C(F)(F)F)C=C1 | 2412.1 | Standard polar | 33892256 | Fluvoxamine,1TBDMS,isomer #1 | COCCCCC(=NOCCN[Si](C)(C)C(C)(C)C)C1=CC=C(C(F)(F)F)C=C1 | 2259.1 | Semi standard non polar | 33892256 | Fluvoxamine,1TBDMS,isomer #1 | COCCCCC(=NOCCN[Si](C)(C)C(C)(C)C)C1=CC=C(C(F)(F)F)C=C1 | 2321.0 | Standard non polar | 33892256 | Fluvoxamine,1TBDMS,isomer #1 | COCCCCC(=NOCCN[Si](C)(C)C(C)(C)C)C1=CC=C(C(F)(F)F)C=C1 | 2580.6 | Standard polar | 33892256 | Fluvoxamine,2TBDMS,isomer #1 | COCCCCC(=NOCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C1=CC=C(C(F)(F)F)C=C1 | 2712.5 | Semi standard non polar | 33892256 | Fluvoxamine,2TBDMS,isomer #1 | COCCCCC(=NOCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C1=CC=C(C(F)(F)F)C=C1 | 2601.2 | Standard non polar | 33892256 | Fluvoxamine,2TBDMS,isomer #1 | COCCCCC(=NOCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C1=CC=C(C(F)(F)F)C=C1 | 2576.3 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Fluvoxamine GC-MS (Non-derivatized) - 70eV, Positive | splash10-000y-9050000000-9f5fd5838cffb95c77dc | 2017-08-28 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fluvoxamine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Fluvoxamine LC-ESI-qTof , Positive-QTOF | splash10-066r-0179000000-511765bf69bd5c60c543 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fluvoxamine , positive-QTOF | splash10-066r-0179000000-511765bf69bd5c60c543 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fluvoxamine 30V, Positive-QTOF | splash10-0udi-0390000000-54678a8e243c405d34d3 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fluvoxamine 40V, Positive-QTOF | splash10-0ue9-0950000000-33c5386b88efe1870f95 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fluvoxamine 20V, Positive-QTOF | splash10-0zi0-0090000000-973c1e0254ef4a22f266 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fluvoxamine 10V, Positive-QTOF | splash10-014i-0029000000-60e771618139ce10e086 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fluvoxamine 50V, Positive-QTOF | splash10-001j-0910000000-865bfd124b5bc4decaea | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvoxamine 10V, Positive-QTOF | splash10-014l-4097000000-bd73d7b04a9cbd6e10a2 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvoxamine 20V, Positive-QTOF | splash10-0006-7191000000-b8ff0c1ca5bbe3302bf6 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvoxamine 40V, Positive-QTOF | splash10-01vx-9260000000-61d88b8b55778271c507 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvoxamine 10V, Negative-QTOF | splash10-014i-1049000000-16bb56f2edbb8d418047 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvoxamine 20V, Negative-QTOF | splash10-0a4i-1191000000-aa43007dad9f770e769d | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvoxamine 40V, Negative-QTOF | splash10-0bvl-9260000000-8b12b73c65cee8c561ed | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvoxamine 10V, Negative-QTOF | splash10-0ab9-0191000000-77ed45ebfa115b7144ad | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvoxamine 20V, Negative-QTOF | splash10-0007-1191000000-d6d1a7703d9ab9b76a74 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvoxamine 40V, Negative-QTOF | splash10-014i-1295000000-6f4d13fd65d715a1afca | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvoxamine 10V, Positive-QTOF | splash10-014i-0049000000-f8a69edae3c7eaf023f6 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvoxamine 20V, Positive-QTOF | splash10-01oy-2191000000-65e65dd93d8b18225121 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvoxamine 40V, Positive-QTOF | splash10-054o-6291000000-6ee0b334022ccdcfbf3c | 2021-09-24 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00176 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00176 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00176 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 4481878 |
---|
KEGG Compound ID | C07571 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Fluvoxamine |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 5324346 |
---|
PDB ID | FVX |
---|
ChEBI ID | 5138 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Dell'Osso B, Allen A, Hollander E: Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2005 Dec;6(15):2727-40. [PubMed:16316311 ]
- Irons J: Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat. 2005 Dec;1(4):289-99. [PubMed:18568110 ]
|
---|